Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Vaccine ; 32(48): 6583-90, 2014 Nov 12.
Article in English | MEDLINE | ID: mdl-24975811

ABSTRACT

Cell culture is now available as a method for the production of influenza vaccines in addition to eggs. In accordance with currently accepted practice, viruses recommended as candidates for vaccine manufacture are isolated and propagated exclusively in hens' eggs prior to distribution to manufacturers. Candidate vaccine viruses isolated in cell culture are not available to support vaccine manufacturing in mammalian cell bioreactors so egg-derived viruses have to be used. Recently influenza A (H3N2) viruses have been difficult to isolate directly in eggs. As mitigation against this difficulty, and the possibility of no suitable egg-isolated candidate viruses being available, it is proposed to consider using mammalian cell lines for primary isolation of influenza viruses as candidates for vaccine production in egg and cell platforms. To investigate this possibility, we tested the antigenic stability of viruses isolated and propagated in cell lines qualified for influenza vaccine manufacture and subsequently investigated antigen yields of such viruses in these cell lines at pilot-scale. Twenty influenza A and B-positive, original clinical specimens were inoculated in three MDCK cell lines. The antigenicity of recovered viruses was tested by hemagglutination inhibition using ferret sera against contemporary vaccine viruses and the amino acid sequences of the hemagglutinin and neuraminidase were determined. MDCK cell lines proved to be highly sensitive for virus isolation. Compared to the virus sequenced from the original specimen, viruses passaged three times in the MDCK lines showed up to 2 amino acid changes in the hemagglutinin. Antigenic stability was also established by hemagglutination inhibition titers comparable to those of the corresponding reference virus. Viruses isolated in any of the three MDCK lines grew reasonably well but variably in three MDCK cells and in VERO cells at pilot-scale. These results indicate that influenza viruses isolated in vaccine certified cell lines may well qualify for use in vaccine production.


Subject(s)
Antigenic Variation , Antigens, Viral/immunology , Madin Darby Canine Kidney Cells/virology , Orthomyxoviridae/growth & development , Virus Cultivation , Animals , Chlorocebus aethiops , Dogs , Ferrets , Hemagglutination Inhibition Tests , Influenza A Virus, H1N1 Subtype , Influenza A Virus, H3N2 Subtype , Vero Cells
2.
Vaccine ; 29(6): 1135-8, 2011 Feb 01.
Article in English | MEDLINE | ID: mdl-21115061

ABSTRACT

As A(H1N1) influenza enters the post-pandemic phase, health authorities around the world are reviewing the response to the pandemic. To ensure this process enhances future preparations, it is essential that perspectives are included from all relevant stakeholders, including vaccine manufacturers. This paper outlines the contribution of R&D-based influenza vaccine producers to the pandemic response, and explores lessons that can be learned to improve future preparedness. The emergence of 2009 A(H1N1) influenza led to unprecedented collaboration between global health authorities, scientists and manufacturers, resulting in the most comprehensive pandemic response ever undertaken, with a number of vaccines approved for use three months after the pandemic declaration. This response was only possible because of the extensive preparations undertaken during the last decade. During this period, manufacturers greatly increased influenza vaccine production capacity, and estimates suggest a further doubling of capacity by 2014. Producers also introduced cell-culture technology, while adjuvant and whole virion technologies significantly reduced pandemic vaccine antigen content. This substantially increased pandemic vaccine production capacity, which in July 2009 WHO estimated reached 4.9 billion doses per annum. Manufacturers also worked with health authorities to establish risk management plans for robust vaccine surveillance during the pandemic. Individual producers pledged significant donations of vaccine doses and tiered-pricing approaches for developing country supply. Based on the pandemic experience, a number of improvements would strengthen future preparedness. Technical improvements to rapidly select optimal vaccine viruses, and processes to speed up vaccine standardization, could accelerate and extend vaccine availability. Establishing vaccine supply agreements beforehand would avoid the need for complex discussions during a period of intense time pressure. Enhancing international regulatory co-operation and mutual recognition of approvals could accelerate vaccine supply, while maintaining safety standards. Strengthening communications with the public and healthcare workers using new approaches and new channels could help improve vaccine uptake. Finally, increasing seasonal vaccine coverage will be particularly important to extend and sustain pandemic vaccine production capacity.


Subject(s)
Drug Industry/methods , Influenza A Virus, H1N1 Subtype/immunology , Influenza Vaccines/immunology , Influenza, Human/epidemiology , Influenza, Human/prevention & control , Pandemics/prevention & control , Drug Approval/methods , Humans , Influenza, Human/virology , International Cooperation
3.
Vaccine ; 27(22): 2907-13, 2009 May 14.
Article in English | MEDLINE | ID: mdl-19366582

ABSTRACT

A meeting was held at NIBSC, UK in July 2007 to discuss the implications of progress in the use of cell culture systems for the manufacture of vaccines against influenza. Issues discussed included the effect of using eggs and different cell types in strain selection, development of seed viruses to be used in production and the nature of the reagents to be used in determining vaccine potency. Future studies to progress the field were reviewed.


Subject(s)
Drug Approval , Influenza Vaccines/adverse effects , Influenza Vaccines/immunology , Orthomyxoviridae/growth & development , Orthomyxoviridae/immunology , Reassortant Viruses/growth & development , Reassortant Viruses/immunology , Humans , Orthomyxoviridae/genetics , Reassortant Viruses/genetics , United Kingdom , Virus Cultivation/methods
4.
Vaccine ; 26 Suppl 4: D23-6, 2008 Sep 12.
Article in English | MEDLINE | ID: mdl-19230154

ABSTRACT

Influenza represents a public health paradox. The virus is responsible for significant death, disease and economic loss. However, despite the availability of safe and efficacious vaccines, uptake is poor. While policy makers increasingly recognize the value of annual immunization, and vaccine supply is increasing, further efforts are required to implement existing vaccination recommendations and drive the long-term demand that supports supply sustainability. This is equally important for pandemic vaccine supply, which will rely on the same production plants and manufacturing approaches. Technological advances and capacity expansions now offer the prospect of billions of doses of vaccine in the event of a pandemic, and the availability of pre-pandemic vaccines for stockpiling and pre-emptive use. As a result, vaccination strategies utilizing pre-pandemic vaccines, combined with vaccines matched to a pandemic strain once available, offer for the first time a viable approach for mitigating an influenza pandemic.


Subject(s)
Disease Outbreaks/prevention & control , Influenza Vaccines/supply & distribution , Influenza, Human/epidemiology , Influenza, Human/prevention & control , Vaccination/statistics & numerical data , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...